 "Dr Reddy's get USFDA nod for acute migraine injection")
The product is available as a pre-filled, ready-to-use, single-dose disposable autoinjector containing 3 mg of sumatriptan. The injection is intended to be given subcutaneously .
This is the first branded product in the company's neurology portfolio. It will be marketed in the United States by Promius Pharma, a wholly-owned specialty company of Dr Reddy's Laboratories.
"This is a major milestone for the company as we continue to bring innovative medicines to patients and physicians," G V Prasad, CEO and co-chairman, Dr Reddy's Laboratories, stated in a release.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app